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Excess serum free fatty acids (FFAs) are fundamental
to the pathogenesis of insulin resistance. With high-
fat feeding, FFAs activate NF-kB in target tissues,
initiating negative crosstalk with insulin signaling.
However, themechanismsunderlyingFFA-dependent
NF-kB activation remain unclear. Here, we demon-
strate that the saturated FA, palmitate, requires
Bcl10 for NF-kB activation in hepatocytes. Uptake of
palmitate, metabolism to diacylglycerol, and subse-
quent activation of protein kinase C (PKC) appear to
mechanistically link palmitate with Bcl10, known as
a central component of a signaling complex that,
along with CARMA3 and MALT1, activates NF-kB
downstream of selected cell surface receptors.
Consequently, Bcl10-deficient mice are protected
from hepatic NF-kB activation and insulin resistance
following brief high-fat diet, suggesting that Bcl10
plays a major role in the metabolic consequences of
acute overnutrition. Surprisingly, while CARMA3
also participates in the palmitate response, MALT1
is completely dispensable, thereby revealing an
apparent nonclassical role for Bcl10 in NF-kB
signaling.INTRODUCTION
The metabolic syndrome is a cluster of conditions that greatly
increases the risk for type 2 diabetesmellitus (T2DM) and cardio-
vascular disease. A key component to the syndrome is chronic
overnutrition and development of obesity (Unger and Scherer,
2010). Changes in adipose tissue that occur in central/visceral
obesity contribute to a systemic, low-grade inflammatory state444 Cell Reports 1, 444–452, May 31, 2012 ª2012 The Authorsnow known as ‘‘metabolic inflammation’’ which impairs insulin
signaling in key tissues including liver, skeletal muscle, and
brain, thereby producing systemic insulin resistance (Gregor
and Hotamisligil, 2011).
While the insulin resistance associated with obesity unfolds
over a long period of time and is associated with changes in
the cellular makeup and function of adipose tissue, there is
also a well-recognized short-term consequence of overnutrition
that is likely due to the direct effects of nutrient excess
(Kleemann et al., 2010; Schenk et al., 2008). This is particularly
notable with the fat overnutrition that characterizes the Western
diet. Under conditions of moderate fat intake, lipoprotein lipase
expressed in the microvasculature releases fatty acids from tria-
cylglycerols contained in circulating chylomicrons as a means
for transferring dietary lipids to adipocytes for subsequent
storage (Miles and Nelson, 2007). In this way, fatty acids ob-
tained directly from the diet do not circulate freely, outside the
confines of chylomicrons or related lipoproteins. In contrast,
even a single high-fat meal results in an increase in serum free
fatty acids (FFAs), a consequence of the ‘‘spillover’’ effect
whereby the lipoprotein lipase-mediated release of fatty acids
exceeds the capacity of fatty acid uptake and storage in adipo-
cytes (Miles and Nelson, 2007). This postprandial elevation in
serum FFAs is only compounded by visceral obesity because
spillover rates are particularly high in the splanchnic vascular
bed, which expands to support the excess visceral fat (Nelson
et al., 2007; Nielsen et al., 2004). In this scenario, FFAs become
a pathologic nutrient, capable of disrupting metabolic homeo-
stasis (Boden, 2011).
Hepatocytes are thought to be a major target for the delete-
rious effects of elevated FFAs, in part, because FFAs released
in the splanchnic bed are delivered through the portal circulation
directly to the liver. Saturated FAs in particular activate the
canonical NF-kB pathway in liver, which thenmediates inhibitory
crosstalk at various steps in insulin signaling pathways and
causes hepatic insulin resistance (Baker et al., 2011). Despite
the implications for the pathogenesis of T2DM, the mechanisms
Figure 1. Palmitate-Dependent NF-kB Acti-
vation in Hepatocytes
(A and B) Time course for canonical NF-kB
pathway activation in HepG2 cells following
palmitate (FFA) treatment.
(C) Effect of IKK2 inhibitor VI (10 mM), an inhibitor of
the canonical pathway kinase, IKKb, on palmitate
(FFA)-dependent NF-kB activation.
(D) Effect of IKKb knockdown on palmitate (FFA)-
dependent NF-kB activation.
(E and F) Palmitate (FFA)-dependent NF-kB acti-
vation in HepG2 cells in the absence or presence
of either 10 mg/ml TLR4 blocking antibody (E) or
50 ng/ml IL-1R antagonist (F).
See also Figure S1.by which FFAs activate NF-kB are still unclear. There are likely
multiple mechanisms at play, with increasing evidence suggest-
ing that cell type- and tissue-specific differences may exist with
regard to FFA-dependent signaling. Considerable data indicate
that some FFAs act as ligands for toll-like receptor 4 (TLR4), ex-
pressed abundantly on macrophages, and therefore signal to
NF-kB in a receptor-dependent manner (Lee et al., 2001; Saberi
et al., 2009; Shi et al., 2006). Other data suggest that FFAs are
taken up by target cells and undergo metabolism to produce
signaling intermediates, such as diacylglycerols (DAGs) and ce-
ramides, which can then signal to NF-kB through protein kinase
C (PKC) intermediates (Erion and Shulman, 2010; Holland and
Summers, 2008; Turban andHajduch, 2011). Finally, FFAmetab-
olites may also induce endoplasmic reticulum stress culminating
in activation of kinases, such as the double-stranded RNA-
dependent protein kinase, that interface with the NF-kB pathway
(Nakamura et al., 2010; Ozcan et al., 2004). These mechanisms
are not mutually exclusive and it is likely that different cells utilize
different mechanisms depending upon the cellular repertoire of
receptors, metabolic enzymes, and signaling intermediates.
In lymphocytes and some related immune cells, a critically
important signaling event mediating adaptive immunity involves
activation of a signaling complex (CBM signalosome) composed
of a scaffolding protein, CARMA1, an adaptor protein, Bcl10,
and an effector protein, MALT1, that communicates with
the NF-kB machinery. In lymphocytes, assembly of the CBM
signalosome first requires T or B cell receptor-dependent PKC
activation and phosphorylation of CARMA1 (Wegener and
Krappmann, 2007). Recently, we found that the CBM signaling
components are present in nonimmune cells including hepato-
cytes, with the highly homologous CARMA3 protein substituting
for CARMA1 (McAllister-Lucas et al., 2007). Further, activation of
the receptor for angiotensin II (AGTR1) on hepatocytes could
also engage PKC-dependent CBM signaling and NF-kB activa-
tion (McAllister-Lucas et al., 2007). As a result, we wondered if
FFA-dependent activation of PKC, through generation of inter-
mediates such as DAG or ceramide, might harness the CBM sig-
nalosome as a means for activating NF-kB; this would represent
the first physiologic example of receptor-independent NF-kBCell Reports 1, 444–4activation through the CBM signalosome.
Results show that palmitate indeed acti-
vates NF-kB in hepatocytes in a Bcl10-dependentmanner. Intriguingly, while CARMA3 also participates
in palmitate-dependent NF-kB activation, MALT1 is completely
dispensable. Further, Bcl10/ mice are protected from hepatic
NF-kB activation following high-fat feeding, and are also pro-
tected from systemic insulin resistance. These findings reveal
another molecular mechanism through which FFAs can commu-
nicate with the canonical NF-kB machinery.
RESULTS
Palmitate Induces Hepatocellular NF-kB with Delayed
Kinetics
High-fat feeding and obesity are associated with increased flux
of FFAs into the circulation, thereby leading to enhanced uptake
of the fatty acids into multiple tissues, including the liver. In order
to mimic the influx of excess FFAs into hepatocytes, we treated
human HepG2 cells with palmitate, a saturated FA found abun-
dantly in the Western diet. We observed a time- and concentra-
tion-dependent induction of IkBa phosphorylation following
palmitate treatment, indicating activation of the canonical
NF-kB pathway (Figure 1A; Figure S1A available online). In this
pathway, stimulation of the multisubunit IkB Kinase (IKK)
complex triggers phosphorylation-dependent proteasomal
degradation of IkBa, thus releasing transcriptionally active
p50/RelA NF-kB dimers for translocation into the nucleus (Baker
et al., 2011). As such, we also observed palmitate-dependent
nuclear accumulation of RelA (Figure 1B). In addition, we demon-
strated that IKK2 inhibitor VI, a selective inhibitor of the canonical
pathway-specific IKKb subunit, blocks palmitate-induced IkBa
phosphorylation, as does siRNA-mediated knockdown of IKKb
protein (Figures 1C and 1D).
Interestingly, NF-kB activation occurred much more slowly
in response to palmitate as compared to interleukin (IL)-1b
(Figure 1A). IL-1b, a proinflammatory cytokine whose level is
elevated during obesity, induces canonical NF-kB activation in
hepatocytes via stimulation of its receptor, IL-1R (Schroder
et al., 2010). IL-1b treatment of hepatocytes induced robust
phosphorylation of IkBa within 5 min, typical for a receptor-
mediated response. In contrast, no significant phosphorylation52, May 31, 2012 ª2012 The Authors 445
of IkBa or RelA nuclear translocation was observed until after
60 min of palmitate treatment, with peak activation occurring
between 90 and 120 min. This difference in the time course
suggests that palmitate stimulates canonical NF-kB signaling
via a mechanism that is distinctly different from that used by
IL-1b and may indicate that palmitate-dependent activation of
NF-kB does not occur via traditional receptor-mediated intracel-
lular signaling.
Neither TLR4 Nor an IL-1b/IL-1R Autocrine Loop
Mediates Palmitate-Dependent NF-kB Activation
in Hepatocytes
We then investigated whether TLR4, a pattern recognition
receptor implicated in FFA-dependent signaling in macro-
phages, myocytes, and adipocytes (Fessler et al., 2009), is
required for palmitate-induced canonical NF-kB activation in
hepatocytes. Previous gene expression profiling studies had
shown that TLR4 expression is quite low in the liver, as
compared to several other tissues (Lattin et al., 2008; Wu et al.,
2009). In particular, expression in liver cells is several orders of
magnitude lower than in macrophages, myoblasts, and adipo-
cytes (Figure S1B). Furthermore, high throughput analysis of
gene transcriptional responses has revealed that treating
primary rat hepatocytes with the classic TLR4 agonist, lipopoly-
saccharide (LPS), does not induce a notable NF-kBgene expres-
sion signature (Deng et al., 2010). With this in mind, we first
evaluated the response of HepG2 cells to LPS; these cells
represent a good model for testing hepatocellular sensitivity to
bona fide TLR4 agonists because, albeit low, levels of TLR4
and its downstream signaling intermediates such as Myd88 are
comparable in HepG2 cells and in primary hepatocytes (Liguori
et al., 2008). We found that, even at high doses, LPS does not
stimulate canonical NF-kB signaling in HepG2 cells (Figure S1C),
consistent with what has been seen with a range of other hepa-
tocyte cell lines (Preiss et al., 2008). Second, we demonstrated
that a-TLR4, a receptor-blocking antibody that prevents LPS-
mediated NF-kB activation in MonoMac-6 macrophages, has
no effect on palmitate-induced IkBa phosphorylation in HepG2
cells (Figure 1E). Together, our results and the gene expression
profiling studies suggest that the TLR4 signaling machinery is
not robustly active in hepatocytes and that palmitate does not
utilize TLR4 to stimulate canonical NF-kB activation in these
cells.
Recent reports demonstrate that palmitate can induce activa-
tion of the NLRP3 inflammasome in macrophages and in liver
(Csak et al., 2011; Vandanmagsar et al., 2011; Wen et al.,
2011). Inflammasomes are large multiprotein complexes that,
when activated by exogenous or endogenous ‘‘danger signals,’’
such as cholesterol crystals, uric acid crystals and amyloid-b
protein, stimulate the cleavage of pro-IL-1b, thereby promoting
maturation and secretion of active IL-1b (Davis et al., 2011).
This could potentially establish a feed-forward, inflammatory
loop due to autocrine IL-1b/IL-1R-dependent NF-kB activation.
We therefore investigated whether the palmitate-dependent
NF-kB activation we observed in hepatocytes occurs via an
IL-1b autocrine loop, a finding that might account for the time
delay required for NF-kB activation. However, we found that
while an IL-1R antagonist peptide (IL-1RA) completely prevents446 Cell Reports 1, 444–452, May 31, 2012 ª2012 The AuthorsNF-kB activation in hepatocytes treated with IL-1b, the peptide
has no effect on palmitate-dependent NF-kB activation
(Figure 1F).
Taken together, these results indicate that the striking time
delay required for palmitate-dependent NF-kB activation is not
explained by an IL-1b autocrine loop, nor is it consistent with
a direct, receptor-mediated response to palmitate, as might
occur if TLR4was present on hepatocytes and capable of recog-
nizing palmitate as an agonist. Instead, we reasoned that the
delay might reflect the need for internalization and metabolism
of palmitate into signaling intermediates capable of stimulating
the NF-kB machinery.
Palmitate-Dependent Canonical NF-kB Activation
in Hepatocytes Requires DAG-Dependent Stimulation
of PKC, but Not Ceramide Production
Upon entering the cell, palmitate can be incorporated into
either of two bioactive metabolites that have been implicated
in NF-kB stimulation and insulin resistance, DAG or ceramide
(Figure 2A) (Deevska and Nikolova-Karakashian, 2011). In order
to determine if ceramide production contributes to the observed
palmitate-induced NF-kB activation in hepatocytes, we evalu-
ated the effect of myriocin, an inhibitor of the rate-limiting
enzyme in ceramide synthesis, serine palmitoyltransferase (SPT)
(Summers, 2010). While myriocin completely prevented palmi-
tate-dependent increases in intracellular ceramide species, it
had no effect on palmitate-dependent IkBa phosphorylation
(Figure 2B). Similarly, cycloserine and fumonisin B1, two other
inhibitors of enzymes catalyzing committed steps in ceramide
synthesis, had no effect on palmitate-dependent IkBa phosphor-
ylation (Figure S2). In contrast, bromoenol lactone (BEL), which
inhibits phosphatidic acid phosphohydrolase (PAP) activity and
prevents the incorporation of palmitate into DAG, andCalphostin
C, a potent inhibitor of DAG-sensitive PKC isoforms, both
blocked palmitate-dependent IkBa phosphorylation (Figures
2C and 2D).
We next attempted to use an siRNA approach to identify
a specific PKC isoform that might be responsible for the palmi-
tate effect. However, initial studies showed that downregulation
of individual isoforms was largely ineffective, suggesting redun-
dancy in the function of multiple PKCs. We therefore used an
alternate approach to test whether the palmitate response
depends on the group of DAG-responsive, conventional/novel
PKC isoforms, or on the group of ceramide-responsive, atypical
PKCs. This approach made use of the well-known ability of
12-O-tetradecanoylphorbol-13-acetate (TPA) to selectively
downregulate DAG-responsive PKC isoforms after prolonged
exposure. As expected, upon treating cells overnight with TPA,
we found that levels of PKCd, an example of a DAG-responsive
isoform, were almost undetectable, while levels of PKCz, an
example of an atypical PKC, were completely unaltered (Fig-
ure 2E). Importantly, this TPA pretreatment completely abolished
palmitate-dependent IkBa phosphorylation (Figure 2E). Taken
together, the results from the use of enzymatic inhibitors and
TPA-mediated PKC downregulation suggest that DAG genera-
tion, but not ceramide generation, and subsequent activation
of conventional/novel PKC isoforms are critical for palmitate’s
ability to stimulate canonical NF-kB signaling in hepatocytes.
Figure 2. Hepatocellular Palmitate Metabolism and the Impact on NF-kB Activation
(A) Schematic of palmitate metabolism.
(B) Lack of an effect of myriocin (10 mM), a ceramide synthesis inhibitor, on palmitate (FFA)-dependent NF-kB activation in HepG2 cells (upper panel). Cellular
levels of three ceramide species (C16, C18, and C20) were induced by palmitate treatment, but induction of all three was blocked by myriocin (lower panel). Error
bars represent the SEM.
(C and D) Effect of DAG synthesis inhibition by BEL (C) or of blocking DAG-sensitive PKC isoforms with Calphostin C (D) on the palmitate (FFA) response.
(E) Overnight pretreatment of HepG2 cells with TPA caused downregulation of DAG-sensitive PKCs (e.g., PKCd), but not atypical PKCs (e.g., PKCz), and
prevented palmitate (FFA)-dependent NF-kB activation. As expected, TPA pretreatment also prevented NF-kB activation in response to Ang II.
See also Figure S2.Bcl10 Is Required for Palmitate-Dependent NF-kB
Stimulation in Hepatocytes
The CBM signalosome, composed of the proteins CARMA1/3,
Bcl10, and MALT1, is assembled in response to cell-surface
receptor-dependent PKC activation and mediates downstream
canonical NF-kB activation. Thus, the signalosome functions
as a bridge linking PKC to the NF-kB machinery, but to date
this has only been demonstrated physiologically in the context
of stimulating a select group of receptors that include the
lymphocyte antigen receptors and a subset of G protein-coupled
receptors (GPCRs) (Blonska and Lin, 2011; Wegener and
Krappmann, 2007). Since our data indicated that PKC activationis required for palmitate to stimulate IkBa phosphorylation,
we investigated whether the CBM signalosome also links
palmitate-dependent PKC activation to stimulation of NF-kB,
but in a unique, receptor-independent fashion. First, we demon-
strated that siRNA-mediated depletion of Bcl10, a central linker
protein required for assembly of the signalosome, prevents
palmitate-dependent stimulation of IkBa phosphorylation in
HepG2 cells (Figures 3A and S3A). This effect of Bcl10 depletion
was also observed in rat H4IIE hepatoma cells, demonstrating
that the requirement of Bcl10 is not a peculiarity of the
HepG2 cells and is not a species-specific phenomenon (Fig-
ure 3B). Bcl10 knockdown also blocked palmitate-dependentCell Reports 1, 444–452, May 31, 2012 ª2012 The Authors 447
Figure 3. Bcl10 Is a Critical Mediator of FFA-Dependent NF-kB Activation in Liver
(A and B) Bcl10 knockdown by siRNA in either human HepG2 (A) or rat H4IIE (B) hepatocytes blocks palmitate (FFA)-dependent NF-kB activation. Activation by
Ang II (1 mM) was included as a positive control, while activation by IL-1b (10 ng/ml) and TNF-a (1 ng/ml) were used as negative controls to demonstrate the
selective impact of Bcl10 knockdown on only certain pathways of IKK activation.
(C) Bcl10 knockdown blocked RelA phosphorylation, another marker of NF-kB activation, but did not significantly impact JNK activation.
(D) Effect of siRNA-mediated knockdown, in HepG2 cells, of each component of the CBM signalosome. CARMA3 knockdown, but not MALT knockdown,
impaired the palmitate (FFA) response.
(E) NF-kB activation in livers taken from WT or Bcl10/ mice following 3 days on either a normal diet (ND) or a 60% HFD.
See also Figure S3.phosphorylation of the RelA NF-kB subunit on Ser536 (Figure 3C).
This phosphorylation event occurs as a consequence of IKKb
activation and contributes to optimal activity of the canonical
NF-kB transcription factor (O’Mahony et al., 2004; Sakurai
et al., 1999). Importantly, we found that the role of Bcl10 in medi-
ating a response to palmitate is relatively specific for the NF-kB
pathway, since Bcl10 knockdown had only a slight effect on
JNK1/2 phosphorylation (Figures 3C and S3B).
Next, we evaluated the contribution of the other principal
components of the CBM signalosome, using a knockdown
strategy. CARMA3 depletion was effective at blocking palmi-
tate-dependent IkBa phosphorylation, but we were surprised
to find that MALT1 depletion was inconsequential (Figure 3D).
In fact, in many experiments the level of IkBa phosphorylation
was somewhat higher in the absence of MALT1.
We then investigated the role of Bcl10 in FFA-dependent
NF-kB activation in hepatocytes in vivo. First, we found that
wild-type (WT) mice on a high saturated fat diet (HFD) responded
with a peak of NF-kB activation in liver, as measured by p-RelA
induction, after about three days (Figure S3C). Strikingly, HFD
did not elicit this response in Bcl10-deficient (Bcl10/) mice448 Cell Reports 1, 444–452, May 31, 2012 ª2012 The Authors(Figure 3E). JNK activation in livers was variable during the
course of the brief HFD, without obvious differences between
WT and Bcl10/ mice (Figure S3D). However, given that Bcl10
knockdown in cultured hepatocytes had a slight impact on
palmitate-dependent JNK1/2 phosphorylation (Figures 3C and
S3B), we cannot completely rule out the possibility that differ-
ences in JNK responsiveness may exist between WT and
Bcl10/mice at some point during HFD and ultimately influence
insulin sensitivity in liver.
Bcl10 Deficiency Protects against High-Fat-Diet-
Induced Insulin Resistance
In the hepatocyte, insulin receptor stimulation leads to phos-
phorylation of the receptor substrate proteins, IRS1 and
IRS2, which then coordinate phosphatidylinositol 3-kinase
(PI3-kinase)-dependent activation of Akt (Taniguchi et al.,
2006). One major function of activated Akt is to then direct the
downregulation of genes required for gluconeogenesis. Several
recent studies suggest that FFA-induced NF-kB activation
contributes to hepatic insulin resistance via inhibitory crosstalk
within the hepatocyte, resulting in blockade of specific steps in
Figure 4. Bcl10 Deficiency Protects from HFD-Induced Insulin Resistance
(A) Palmitate (FFA)-dependent inhibition of insulin signaling in HepG2 cells.
(B) Bcl10 knockdown by siRNA in HepG2 cells restores insulin sensitivity in the face of palmitate (FFA) pretreatment.
(C and E) GTTs following 1week (C) on normal diet (ND) versus 60%HFD (n = 3–7 per group), or following 6weeks (E) on ND versus 45%HFD (n = 4–10 per group).
Data are mean ± SEM. *p < 0.05.
(D and F) Plasma insulin levels during GTTs. Data are mean ± SEM. **p < 0.01.
See also Figure S4.downstream insulin signaling pathways (Arkan et al., 2005; Cai
et al., 2005; Kim et al., 2001; Yuan et al., 2001). Consistent
with this notion, we found that palmitate pretreatment of
HepG2 cells caused a concentration- and time-dependent inhi-
bition of insulin-responsive Akt phosphorylation, an effect that
temporally followed NF-kB activation (Figures 4A and S4A).
However, this effect of palmitate was not reversed by myriocin,
cycloserine, or fumonisin B1, inhibitors of ceramide synthesis
(Figure S4B). In contrast, siRNA-mediated depletion of Bcl10
did reverse the palmitate-dependent inhibition, restoring insulinsensitivity to the cells as measured by Akt phosphorylation
(Figure 4B). These results indicate that Bcl10 is required for
palmitate to inhibit insulin signaling and implicate Bcl10 as
a factor in promoting hepatocellular insulin resistance.
We next evaluated the contribution of Bcl10 to insulin resis-
tance in vivo. We performed glucose tolerance tests (GTTs)
with WT or Bcl10/ mice that had been fed either a 60% HFD
for 1 week or a 45% HFD for 6 weeks. While weight gain was
not significantly different between the WT and Bcl10/ groups
(Figure S4C), this analysis revealed that under both diets,Cell Reports 1, 444–452, May 31, 2012 ª2012 The Authors 449
Bcl10/mice maintained better glucose control throughout the
GTTs compared to WT mice (Figures 4C and 4E). Importantly,
Bcl10/ mice achieved better glucose control with less insulin
production, indicating that the effect of Bcl10 deficiency is to
protect the mice from HFD-induced insulin resistance (Figures
4D and 4F). These analyses demonstrate that Bcl10 plays
a central role in the development of HFD-induced insulin resis-
tance, in vivo.
DISCUSSION
Excess FFAs are key to the pathogenesis of the metabolic
syndrome and likely play a role in both the acute insulin resis-
tance seen after short-term high-fat feeding, and the chronic
insulin resistance associated with obesity. FFAs activate various
signaling pathways that inhibit the intracellular actions of insulin;
chief among these is the NF-kB pathway. Nevertheless, the
mechanisms by which FFAs activate NF-kB are incompletely
understood and probably vary depending on the target cell type.
We have identified a mechanism by which palmitate activates
NF-kB in hepatocytes. In this case, activation depends upon
intracellular accumulation of palmitate, metabolism to DAG,
and activation of conventional/novel PKCs. Our data also
demonstrate a critical downstream role for Bcl10 and CARMA3,
supporting a model whereby activated PKC then stimulates
the CARMA-Bcl10-MALT1 (CBM) signalosome, a signaling
complex that until now has only been associated with cell
surface receptor-dependent signaling to NF-kB (Wegener and
Krappmann, 2007). One critical difference, however, is high-
lighted by the fact that MALT1 is completely dispensable for
the palmitate response. This suggests that palmitate signaling
to NF-kB is not completely analogous to the now classically
understood mechanism whereby selected cell surface recep-
tors (e.g., TCR, AGTR1) signal to NF-kB. In the later case,
signaling proceeds through the CBM signalosome with MALT1
acting as an obligatory effector protein, coordinating the down-
stream activation of the NF-kB machinery. In the case of palmi-
tate, signaling proceeds to NF-kB through CARMA3 and Bcl10,
but in a way that bypasses MALT1. This observation suggests
that Bcl10 may have unexplored functions related to canonical
NF-kB activation that, with certain stimuli, do not involve
MALT1. Evidence for this concept can also be seen from work
on Malt1/ mice that do not completely phenocopy Bcl10/
mice with respect to BCR-dependent NF-kB signaling (Ruland
et al., 2003). Similarly, retinoic acid inducible gene I (RIG-1)-
responsive cytokine production appears to depend on Bcl10
and subsequent NF-kB activation, but not on MALT1 (Poeck
et al., 2010). Deciphering the MALT1-independent functions of
Bcl10 will represent a major new frontier for the field of NF-kB
signaling research.
Work presented here represents a paradigm shift in our under-
standing of how at least some components of the CBM signalo-
some can be engaged. Specifically, the findings suggest that
coupling of CBM components at cell-surface receptor microdo-
mains does not necessarily need to occur for downstream
NF-kB activation. Additional work will be needed to fully deter-
mine how CARMA3, which is known to connect the signalosome
with receptors and is the predominant CARMA family member450 Cell Reports 1, 444–452, May 31, 2012 ª2012 The Authorsexpressed in nonimmune cells, can be stimulated by palmitate
metabolism and in the absence of receptor engagement. Since
this signaling cascade likely occurs in the cytoplasm, and not
at the cell surface, it is intriguing to speculate that the related
CARD9 protein is also required; this scaffolding protein is struc-
turally similar to CARMA3 and can be regulated by PKC, but
lacks domains that are needed for membrane localization
(Hara and Saito, 2009; Strasser et al., 2012). Although it has
mostly been studied in myeloid cells, perhaps CARD9 could
work in concert with CARMA3 tomediate the palmitate response
in hepatocytes.
Our studies highlight the acute effects of FFAs on hepatocel-
lular function and reveal a mechanism by which short-term
high-fat feeding impacts systemic insulin sensitivity. These
studies also underscore the notion that liver is one of the earliest
sites affected by nutrient imbalance, in the form of excess dietary
fat. We propose a model for hepatic insulin resistance during
high-fat feeding and subsequent obesity that takes into account
both (1) acute effects of excess fat as a pathologic dietary
nutrient and (2) chronic effects that involve the participation of
inflammatory cells and the recently identified contribution of
the inflammasome (Figure S4D). This model suggests that
FFAs act through varied mechanisms that depend on both the
cell type affected and the temporal stage in the development
of insulin resistance. A more complete understanding of the
pathogenesis of insulin resistance will require an understanding
of how these varied mechanisms work in an integrated manner
over time.
EXPERIMENTAL PROCEDURES
Mice
Bcl10/ mice have been described (Ruland et al., 2001). Mice were back-
crossed onto the C57BL/6J background for more than ten generations and
were used between 2 and 3 months of age for all experiments involving
HFD. All animal studies were approved by the University Committee on Use
and Care of Animals (UCUCA) at The University of Michigan.
Fatty Acid Preparation and Treatment
FFAs were prepared as described previously (Cousin et al., 2001). Briefly,
a 100 mM stock of palmitate (Sigma; Cat. No. P5585) was prepared in 0.1 M
NaOH by heating to 70C. Palmitate was then complexed with BSA to make
a 5 mM working stock via dropwise addition to 10% endotoxin/FA-free Frac-
tion V BSA (MP Biomedicals; Cat. No. 194772), while vortexing. The palmitate/
BSA mixture was sterile filtered (0.2 mM pore size) before use.
Cell Culture and Western Analysis
Human hepatocellular carcinoma (HepG2) cells and H4IIE rat hepatocytes
were obtained from ATCC and maintained in DMEM with 10% FBS.
MonoMac-6 cells were cultured in RPMI with 10% FBS. Cells were treated
and analyzed as detailed in the Extended Experimental Procedures.
RNA Interference
Cells were reverse transfected with siRNAs using Lipofectamine RNAiMAX
(Invitrogen). Specific siRNA reagents are listed in the Extended Experimental
Procedures.
Ceramide Quantification
Cells were extracted with a mixture of methanol and chloroform, including
internal standards (D31-C16, C17, and C25 ceramide). Extractions were
then dried under nitrogen gas and reconstituted in 100 ml of mobile phase
B (60:40 acetonitrile:isopropanol). Analyses were carried out using liquid
chromatography-triple quadrupole mass spectrometry (LC-QQQ) in the
University of Michigan Lipidomics Core Lab, and data analyzed using the
Agilent masshunter suite of programs, version B.04.00.
High-Fat-Diet Studies
Male WT or Bcl10/ mice were fed high-fat chow from Research Diets, Inc.
containing either 60% calories from fat (D12492) for 1 week, or 45% calories
from fat (D12451) for 6 weeks. GTTs were performed following a 6 hr fast by
administering IP glucose (1.5 g/kg). Blood glucose levels weremeasured using
the OneTouch Ultra 2 glucose meter (Lifescan). Serum insulin was measured
by ELISA (Crystal Chem, Inc., Cat No. 90080), 15 min into the GTT.
Statistics
Data are expressed as mean ± SEM. Differences between groups were
compared using unpaired Student’s t tests. p values of < 0.05 were considered
significant.
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